Financial Performance - The company reported a decline in performance, with specific reasons detailed in the "Analysis of Four Main Businesses" section of the report[5]. - The company's operating revenue for 2024 was ¥5,829,800,576.60, a decrease of 14.94% compared to ¥6,853,359,543.02 in 2023[21]. - The net profit attributable to shareholders for 2024 was ¥317,075,752.08, representing a significant decline of 242.76% from ¥567,448,293.44 in 2023[21]. - The net cash flow from operating activities decreased by 40.19% to ¥122,341,832.53 in 2024, down from ¥204,544,610.05 in 2023[21]. - The company's basic earnings per share for 2024 was -¥0.7668, a decrease of 240.29% from ¥0.5466 in 2023[21]. - The company reported a total of ¥40,433,908.96 in non-recurring gains and losses for 2024, compared to ¥7,604,237.83 in 2023[28]. - The company experienced a negative net profit for all four quarters of 2024, with the fourth quarter showing a net loss of ¥265,404,923.97[24]. - The net profit attributable to the company, after deducting non-recurring gains and losses, was a loss of ¥493,091,896.83, a decline of 259.33% compared to the previous year[61]. - The comprehensive gross profit margin for the main business was 25.87%, down 5.57% year-on-year[61]. Strategic Outlook - The company plans to enhance its future development strategies as outlined in the "Outlook for Future Development" section[5]. - The company aims to become a leading global pharmaceutical equipment provider by around 2030, focusing on a comprehensive solution for pharmaceutical production 4.0[45]. - The company is enhancing its brand influence in international markets, with a steady increase in overseas market share[49]. - The company aims to leverage its technological advantages and international strategies to enhance competitiveness in the mid-to-high-end market[39]. - The company plans to further expand its international market presence by segmenting global markets into five major regions, improving local responsiveness[69]. Market Position and Industry Trends - The company is positioned as a leading enterprise in the pharmaceutical equipment industry, focusing on providing specialized and intelligent solutions[31]. - The global pharmaceutical equipment market is projected to exceed $50 billion in 2024 and $80 billion by 2030, with a CAGR of approximately 6-8%[32]. - China's pharmaceutical manufacturing market is expected to reach $191.7 billion in 2024, with a CAGR of about 7.5% from 2024 to 2032[37]. - The demand for personalized, small-batch, and multi-variety production is increasing, driving a shift towards modular and flexible equipment[34]. - The company is benefiting from the upgrade of the pharmaceutical industry and is transitioning towards high-end manufacturing, enhancing its international competitiveness[31]. Product Development and Innovation - The company has developed a digital water technology product chain, providing lifecycle services for pharmaceutical water, water treatment, wastewater treatment, and resource utilization, while also expanding applications to new energy, electronic semiconductors, and fine chemicals[50]. - The company has expanded its product offerings to include a comprehensive skincare and daily chemical solution, exemplified by the successful establishment of a smart beauty factory for Shangmei Co., integrating industrial automation, intelligent control, and information management[50]. - The company has successfully developed a series of specialized robots for clean and sterile environments, addressing the market's demand for high-precision and flexible production[55]. - The company has introduced advanced processing techniques for various materials, improving product durability and market competitiveness[51]. - The company has launched a new sterilization logistics system targeting vials, with a production speed of 3-4 packages per minute[90]. Financial Management and Investments - The company reported a fair value change of ¥3,903,335 in financial assets, with a total of ¥630,775,465 at the end of the period[104]. - The company issued 10 million convertible bonds with a total fundraising amount of ¥100,000,000, netting ¥98,681,460 after deducting issuance costs[112]. - The company has ongoing significant non-equity investments, but specific details were not disclosed[107]. - The company has committed to various investment projects with a total investment amount of RMB 98.6 million, with a progress rate of 98.2%[114]. - The company plans to use RMB 154.3252 million to replace self-raised funds that were previously invested in fundraising projects[115]. Governance and Compliance - The company adheres to strict governance practices, ensuring compliance with laws and regulations, and enhancing risk prevention capabilities[135]. - The board of directors operates in accordance with legal requirements, with a focus on diligent performance of duties and responsibilities[138]. - The company has implemented a transparent performance evaluation and incentive mechanism for its directors and senior management[140]. - The company ensures timely and accurate information disclosure, adhering to relevant regulations and providing equal access to all investors[143]. - The internal control audit report issued a standard unqualified opinion, confirming the effectiveness of the financial reporting internal controls[200]. Human Resources and Employee Management - The total number of employees at the end of the reporting period was 7,005, including 4,012 at the parent company and 2,993 at major subsidiaries[184]. - The company has implemented a performance-oriented salary system, linking salary increases directly to performance assessments[186]. - The company has established a comprehensive talent development system, including training plans for new employees and ongoing professional development for existing staff[187]. - The company has reduced its R&D personnel by 29.67% from 2,720 in 2023 to 1,913 in 2024[93]. - The company has a total of 912.9 million shares of restricted stock that will be canceled due to performance assessment failures, affecting 559 incentive recipients[192].

Financial Performance - The company's operating revenue for Q1 2025 was ¥1,083,171,677.45, a decrease of 22.19% compared to the same period last year[4]. - The net profit attributable to shareholders was a loss of ¥8,556,904.43, an improvement of 59.00% from a loss of ¥20,871,739.14 in the previous year[4]. - Basic and diluted earnings per share were both -¥0.0145, showing a 59.04% improvement from -¥0.0354 in the previous year[4]. - The company's net profit margin was impacted by a significant increase in financial expenses, which rose to ¥22,886,756.40 from ¥10,384,913.00, reflecting a 120% increase[20]. - The net profit for the current period is -13,440,239.56, an improvement from -20,716,801.32 in the previous period, representing a decrease in net loss of approximately 35%[21]. - The total comprehensive income for the current period is 29,363,025.88, compared to -50,418,878.54 in the previous period, indicating a significant recovery[21]. - The total operating profit for the current period is -24,633,247.88, an improvement from -26,895,103.40 in the previous period, showing a reduction in operating losses[21]. Cash Flow - The net cash flow from operating activities improved by 67.85%, amounting to a net outflow of ¥147,730,837.30, compared to a net outflow of ¥459,497,946.67 in the same period last year[4]. - Cash flow from operating activities shows a net outflow of -147,730,837.30, an improvement from -459,497,946.67 in the previous period[23]. - Cash flow from investing activities has a net outflow of -119,669,546.19, compared to -868,984,903.03 in the previous period, indicating reduced investment losses[23]. - Cash flow from financing activities shows a net inflow of 109,815,057.03, a decrease from 1,102,167,793.19 in the previous period, reflecting a reduction in financing activities[24]. Assets and Liabilities - Total assets at the end of the reporting period were ¥13,204,719,138.23, a decrease of 0.80% from the end of the previous year[4]. - Current liabilities totaled ¥7,182,337,198.32, down from ¥7,347,852,543.54, indicating a reduction of approximately 2.3%[19]. - The company's cash and cash equivalents decreased to ¥1,149,546,287.64 from ¥1,278,390,795.81, a decline of 10.1%[18]. - The cash and cash equivalents at the end of the period amount to 810,399,084.13, compared to 279,193,839.84 at the end of the previous period, showing an increase in liquidity[24]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 26,863[12]. - The largest shareholder, Changsha Chutian Investment Group, holds 38.07% of shares, totaling 224,706,614 shares[12]. - Hunan Caixin Jingxin Investment Partnership holds 2.68% of shares, totaling 15,816,000 shares[12]. - Liu Yan, an individual shareholder, holds 1.99% of shares, totaling 11,722,250 shares[12]. - The top 10 shareholders account for a significant portion of the company's equity, with the largest shareholder alone holding over 38%[12]. - The company has no preferred shareholders as indicated in the report[14]. - There are no changes in the number of restricted shares for key executives during the reporting period[15]. - The total number of restricted shares at the end of the period is 14,118,283 shares[15]. - The report indicates that key executives have locked shares that can be released gradually over their tenure[15]. - The company has not engaged in any share lending or borrowing activities during the reporting period[12]. Cost Management - Research and development expenses decreased by 34.14%, amounting to a reduction of ¥49,391,500 compared to the previous year[9]. - The company implemented cost reduction and efficiency enhancement measures, resulting in a 16.86% decrease in period expenses compared to the previous year[8]. Investment and Financing - Investment income increased by 424.89%, amounting to an increase of ¥1,430,200 compared to the previous year due to higher returns from bank wealth management products[9]. - The company reported a significant decrease in financing cash flow, down 90.04% to a net outflow of ¥99,235,270, primarily due to the absence of convertible bond issuance in the current period[10]. Revenue and Sales - The report indicates that sales revenue from goods and services was 1,404,767,950.05, down from 1,743,978,201.95 in the previous period, indicating a decline of approximately 19%[23]. - Total operating revenue for the current period was ¥1,083,171,677.45, a decrease of 22.2% compared to ¥1,392,029,678.89 in the previous period[20]. - Total operating costs amounted to ¥1,123,822,892.53, down 22.1% from ¥1,443,898,305.35 in the previous period[20]. Project Updates - The company has extended the timeline for the "Medical Equipment and Materials Technology Research Center Project" to March 2026, reflecting a cautious approach to current industry conditions[17]. - The board decided not to adjust the conversion price of the "Chutian Convertible Bonds" downward, maintaining the current terms for the next three months[16].

董秘： 您好！为保持2024年度报告与2025年一季度报告同步披露，故向深交所申请对年报披露时间进 行了调整，具体业绩情况届时请查阅相关报告。谢谢！ 当日关注点 交易信息汇总：4月24日主力资金净流出36.61万元，散户资金净流出63.22万元，而游资资金净流 入99.83万元。 交易信息汇总 董秘最新回复 投资者： 董秘您好，公司的产品对美国加征关税有没有影响，占比多少，今后是否加强欧洲布局 董秘： 您好！公司产品目前出口美国占总收入比非常小。公司将持续加大欧洲市场的拓展，进一步提 升在欧洲市场的占有率。以头部制药企业和高价值客户为主，对标国际头部制药装备同行，进一步提升 国际销售业务的利润水平。持续构建楚天科技在国际上的品牌影响力，持续深化国际销售及服务的本土 化策略，打造以高性价比、高效服务的品牌形象。谢谢！ 投资者： 贵公司年报怎么调整到29号了，是因为业绩太差了吗 截至2025年4月24日收盘，楚天科技(300358)报收于6.81元，下跌0.87%，换手率1.01%，成交量5.83万 手，成交额3993.21万元。 4月24日，楚天科技的资金流向情况如下：主力资金净流出36.61万元；游资资金净流 ...

4月2日，楚天科技今日收盘7.74元，上涨4.74%，最新市净率1.02，创14天以来新低，总市值45.69亿 元。 截至2024年三季报，共有32家机构持仓楚天科技，其中基金32家，合计持股数647.66万股，持股市值 0.44亿元。 楚天科技股份有限公司主营业务为制药装备的研发、设计、生产、销售和服务。主要产品为无菌制剂解 决方案及单机、检测包装解决方案及单机、生物工程解决方案及单机、固体制剂解决方案及单机、制药 用水装备及工程系统集成、EPC工程设计服务。公司已发展成为国内制药装备行业领军企业之一，同时 也成为了全球医药装备行业的知名企业之一。 最新一期业绩显示，2024年三季报，公司实现营业收入41.71亿元，同比-18.75%；净利润-187253063.9 元，同比-165.18%，销售毛利率25.94%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13楚天科技-29.0214.411.0245.69亿行业平均 46.8850.714.88109.12亿行业中值33.6731.142.5548.71亿1硕世生物-1962.70-1962.701.2340.55亿2诺唯 赞-584.37 ...

Summary of Key Points Core Viewpoint The announcement details the conversion of convertible bonds into shares of Chutian Technology Co., Ltd., highlighting the bond issuance, conversion status, and changes in the company's total share capital. Group 1: Convertible Bond Issuance - The company issued convertible bonds with a total face value of RMB 100 million, net proceeds amounting to RMB 98.68 million [1] - The bonds were approved by the China Securities Regulatory Commission and listed on the Shenzhen Stock Exchange on February 29, 2024 [2] Group 2: Conversion Details - The conversion period for the bonds is from August 6, 2024, to the maturity date, with an initial conversion price set at RMB 10.00 per share, later adjusted to RMB 8.00 per share [2][3] - As of the end of the first quarter of 2025, a total of 190 bonds were converted into 2,362 shares, leaving 9,999,810 bonds outstanding with a total face value of RMB 999.98 million [6] Group 3: Share Capital Changes - The total share capital increased from 590,304,611 shares to 590,304,736 shares due to the conversion, with a net increase of 125 shares [6] - The proportion of restricted shares held by executives remained stable, with a slight decrease in the number of locked shares due to executive turnover [6] Group 4: Other Information - Investors can refer to the full terms of the convertible bonds in the company's prospectus published on January 29, 2024 [7]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、楚天转债（债券代码：123240）转股期限为 2024 年 8 月 6 日至 2030 年 1 月 30 日，最新有效的转股价格为人民币 8.00 元/股。 2、2025 年第一季度，共有 10 张"楚天转债"完成转股（票面金额共计 1,000 元人民币），合计转成 125 股"楚天科技"股票（股票代码：300358）。 3、截至 2025 年第一季度末，楚天科技股份有限公司（以下简称"公司"） 剩余可转换公司债券（以下简称"可转债"）为 9,999,810 张，剩余票面总金额 为 99,998.10 万元人民币。 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司 自律监管指引第 15 号——可转换公司债券》的有关规定，公司现将 2025 年第一 季度可转债转股及公司总股本变化情况公告如下： 一、可转换公司债券发行基本情况 | 证券代码：300358 | 证券简称：楚天科技 | 公告编号：2025-014 | 号 | | --- | --- | --- | --- | | 债券代 ...

| 证券代码：300358 | 证券简称：楚天科技 | 公告编号：2025-015 | 号 | | --- | --- | --- | --- | | 债券代码：123240 | 债券简称：楚天转债 | | | 关于部分控股子公司通过高新技术企业认定的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 楚天科技股份有限公司（以下简称"公司"）控股子公司楚天智能机器人（长 沙）有限公司（以下简称"楚天机器人"）、楚天源创生物技术（长沙）有限公 司（以下简称"楚天源创"）、楚天思优特生物技术（长沙）有限公司（以下简 称"楚天思优特"）、楚天长兴精密制造（长沙）有限公司（以下简称"楚天长 兴"）于近日收到了由湖南省科学技术厅、湖南省财政厅、国家税务总局湖南省 税务局联合颁发的《高新技术企业证书》，具体情况如下： 楚天科技股份有限公司 4 、 楚 天 长 兴 本 次 认 定 系 高 新 技 术 企 业 的 首 次 认 定 。 证 书 编 号 ： GR202443001245，发证时间：2024 年 11 月 1 日，有效期三年。 根据国家对高新技术企业的相关税收优惠 ...

Core Viewpoint - The company has announced a change in its continuous supervision representative from Guo Limin to Li Wei, as part of its ongoing convertible bond issuance and listing on the Growth Enterprise Market [1]. Group 1: Company Announcement - Chutian Technology Co., Ltd. has received a letter from its sponsor, Guojin Securities, regarding the replacement of the continuous supervision representative due to the original representative's change in work responsibilities [1]. - The new representatives for the continuous supervision of the company's convertible bond issuance are Yin Baikuan and Li Wei, ensuring the orderly continuation of supervision [1]. - The company expresses gratitude for Guo Limin's contributions during the supervision period [1]. Group 2: Representative Profile - Li Wei holds a Master's degree in Business Administration and has been engaged in investment banking since 2010, with extensive experience in various projects including mergers and acquisitions and IPOs [3]. - His experience includes significant projects such as the acquisition of German Romaco and the IPO of Honghui Fruits and Vegetables [3].

| 证券代码：300358 | 证券简称：楚天科技 | 公告编号：2025-013 | 号 | | --- | --- | --- | --- | | 债券代码：123240 | 债券简称：楚天转债 | | | 楚天科技股份有限公司 关于更换持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 楚天科技股份有限公司（以下简称"公司"）于近日收到保荐机构国金证券 股份有限公司（以下简称"国金证券"）出具的《关于更换楚天科技股份有限公 司持续督导保荐代表人的函》，国金证券作为公司向不特定对象发行可转换公司 债券并在创业板上市的持续督导机构，原委派保荐代表人郭丽敏女士因工作内容 变动，无法继续从事对公司的持续督导工作。为保证持续督导工作的有序进行， 国金证券现委派保荐代表人李伟先生（简历详见附件）接替郭丽敏女士继续履行 持续督导工作。 本次保荐代表人变更之后，负责公司向不特定对象发行可转换公司债券并在 创业板上市的持续督导保荐代表人为尹百宽先生和李伟先生，持续督导期间至 2026 年 12 月 31 日。 公司董事会对郭丽敏女士在公司向不特定对象 ...

以下文章来源于非凡油条 ，作者非凡油条 非凡油条 . 非凡油条新家 降低对石油的依赖。 作者 | 非凡油条 来源 | 非凡油条 （ID：ffyoutiao） 一场惊天变局，在不知不觉中发生了。 去年中国原油进口量为5.53亿吨，同比下降1.9%。 除疫情影响外，这是近二十年中国原油进口量第一次下降。 能源的变迁，也在让就建立在能源上的工业体系，发生着翻天覆地的变化。 削减石油消费，再造能源产业 石油，是重要的化工原料，所以我们目前无法完全抛弃石油，而是要降低对石油的依 赖。 中国就是这么做的，去年化工用油还增长了7.3%，但成品油消费为3.9亿吨，同比下降 了2.4%。 成品油消费下降，新能源车功不可没。2024年，中国新能源汽车保有量突破3000万 辆，占汽车总量比重超过8%，累计替代汽油约2800万吨。 难道是中国能耗见顶了？并不是。 去年全社会用电量同比增长6.8%，仍然是 全球第一 的吞电巨兽。 而在发电端，中国新能源发电装机达14.5亿千瓦，去年首次超过火电装机规模。 可见中国正在做的，是 发展新能源，降低对石油的依赖。 中国新能源车渗透率已经超过40%，保有量还会继续增长，减少成品油消费，预计到 ...